March 6, 2018 / 12:11 PM / 5 months ago

BRIEF-Bristol-Myers Squibb's Opdivo Now The First And Only FDA-Approved PD-1 Inhibitor To Offer Every Four-Week Dosing

March 6 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL-MYERS SQUIBB'S OPDIVO® (NIVOLUMAB) NOW THE FIRST AND ONLY FDA-APPROVED PD-1 INHIBITOR TO OFFER EVERY FOUR-WEEK DOSING

* BRISTOL-MYERS SQUIBB - ‍ OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS​

* BRISTOL-MYERS SQUIBB - FDA APPROVES OPDIVO LABEL UPDATE OFFERING FLEXIBLE FLAT-DOSING OPTIONS EVERY TWO WEEKS (240 MG) OR EVERY FOUR WEEKS (480 MG)​

* BRISTOL-MYERS SQUIBB CO - ‍DOSING SCHEDULE UPDATES FOR AN ADDITIONAL APPROVED INDICATION FOR OPDIVO MAY BE SUBMITTED TO FDA IN FUTURE FOR OPDIVO​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below